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A B S T R A C T
Background: Dysregulation of angiogenesis and lymphangiogenesis could participate in psoriasis
pathogenesis. Analysis of nascent psoriasis lesions should help at identifying early vascular anomalies.
Objective: To analyse vascular development, angiogenesis and lymphangiogenesis markers expression in
uninvolved skin in psoriatic patients (N), early psoriasis lesions or pinpoints (PP) and psoriasis plaques (PSO).
Methods: Skin biopsies were taken in 17 patients in N and in PSO and/or PP. ThemRNA steady-state level
of angiogenesis and lymphangiogenesis markers was measured by RT-PCR. Immunohistochemistry was
performed for von Willebrand factor, podoplanin, Ki-67 and VEGFR3. Blood (BV) and lymphatic (LV)
vessels expansion was measured by computer-assisted morphometry.
Results: Clinical and epidermal aspects indicated that PP are intermediate between N and PSO. While
total BV area was already increased in PP similarly to PSO as compared to N, LV area in PP was
intermediate between N and PSO. Mean LV size was identical in N and PP and increased in PSO, mean BV
size in PP being intermediate between N and PSO. VEGF-A 189 variant was increased in PP as compared
to N and PSO. As compared to N, angiogenesis markers (VEGF-A isoforms, PlGF, VEGFR2, NRP-1), VEGF-C
and NRP-2 were similarly increased in PP and PSO. Keratin 16 and the lymphangiogenesis markers
(VEGFR3, prox-1) were intermediate in PP.
Conclusion: These data suggest that the expansion of lymphatic vessels occurs after blood vascular
development in psoriasis. Expansion of BV in PP could be followed by vessel enlargement during
progression to PSO, in parallel with a decreased VEGF-A 189/VEGF-A 121 balance in plaques.
 2010 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights
reserved.
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Psoriasis, a common inﬂammatory disease of the skin affecting
2–3% of the European population, is in part genetically determined
[1]. Histological features of psoriasis include epidermal hyperpla-
sia, impaired epidermal differentiation, accumulation of inﬂam-
matory cells and excessive angiogenesis with enlarged, tortuous
and hyperpermeable dermal blood vessels [2]. One of the earliest
events in the development of psoriatic plaques is a vascular
network expansion, which occurs before epidermal changes [3,4]
and persists after clearance of the clinical lesions [5].* Corresponding author at: Laboratory of Connective Tissues Biology, Centre
Hospitalier Universitaire de Lie`ge, B 23, B-4000 Sart Tilman, Belgium.
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doi:10.1016/j.jdermsci.2009.12.006Among the numerous mediators governing vascular expansion
[6], vascular endothelial growth factors (VEGF) family largely
participates in the development of the skin lesions in psoriasis [7].
VEGF-A induces blood endothelial cell (EC) proliferation and
increased vascular permeability by activating two related tyrosine-
kinase receptors, VEGFR1 andVEGFR2. VEGF-A binding on VEGFR2,
which is themajor signaling receptor on the surface of EC, is further
potentiated by interaction with neuropilin-1 (NRP-1) acting as a
co-receptor [8]. In psoriatic lesions, VEGF-A overexpressed in the
activated epidermal cells is responsible for the expression of its
own receptor-2 in EC [7]. Alternative splicing of the VEGF-A pre-
mRNA generates at least six molecular variants that display
biological characteristics related to exons combination. The major
isoforms are VEGF-165 and VEGF 121. VEGF 206, 189 and, to a
lesser extent, VEGF 165 contain heparin-binding domains allowing
their sequestration within the extracellular matrix, which can be
reversed by proteolysis [8]. VEGF 121 and a new isoform, VEGFy Elsevier Ireland Ltd. All rights reserved.
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Table 1
Characteristics of the patients included in the study. F, female; M, male; N,
uninvolved psoriatic skin, PP, early psoriasis lesion, PSO, psoriasis plaque.
Patient Age Gender PASI score Site Types of lesions
1 34 F 12 Abdomen N, PSO
2 31 M 14 Arm N, PSO
3 68 M 19 Buttock N, PSO
4 50 M 30 Leg N, PSO
5 28 M 5 Leg N, PSO
6 46 M 13 Buttock N, PSO
7 43 M 10 Arm N, PSO
8 32 M 22 Abdomen N, PP, PSO
9 70 F 18 Back N, PP, PSO
10 28 M 28 Back N, PP, PSO
11 42 M 11 Arm N, PP
12 40 M 14 Back N, PP
13 25 F 11 Abdomen N, PP
14 59 F 17 Arm N, PP
15 25 M 19 Arm N, PP
16 38 F 15 Buttock N, PP
17 47 M 11 Arm N, PSO
Fig. 1. Pinpoint lesion. This photograph shows psoriasis lesions including a pinpoint
lesion (arrow).
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and psoriasis human skin [9,10], are freely diffusible. Placental
growth factor (PlGF) is another important mediator of skin
angiogenesis [11] that may directly activate VEGFR1, thus
potentiating VEGF activity, and that also promotes bone-mar-
row-derived precursor cells mobilization and monocyte chemo-
taxis [11,12]. As for VEGF-A, alternative exon splicing produces
four isoforms, PlGF-1 to -4, that differ by their binding afﬁnities for
heparin [13,14]. PlGF-2 is membrane-associated; PlGF-1 is
diffusible while PlGF-3 and PlGF-4 are expressed in placenta
and umbilical vein EC [14] but not in adult skin [10].
New insights have been obtained into the mechanisms
governing lymphatic development and function during the last
decade [15]. VEGF-C and -D have been identiﬁed as growth factors
stimulating lymphangiogenesis [16]. The activation of their
tyrosine-kinase receptor VEGFR3 leads to the proliferation of
lymphatic EC while targeted deletion of VEGF-C in mice impairs
the development of small lymphatic vessels and is lethal [16].
VEGFR3 is expressed in venous as well as lymphatic EC during
embryogenesis but only in lymphatic EC after birth except for the
fenestrated blood vessels of some organs [17]. Neuropilin-2a (NRP-
2a) is a receptor for the semaphorins and acts as a co-receptor for
VEGF-A and VEGF-C. It enhances some of the biological responses
elicited by these growth factors such as EC survival and migration,
through interaction with VEGFR2 and VEGFR3 [18,19]. Prox-1 is a
homeotic protein that speciﬁes the lymphatic cell fate by
reprogramming the transcriptome of embryonic venous EC [20].
Little is known about the mechanisms and the chronology of
lymphatic development in psoriasis lesions [21,22].
Psoriasis lesions start as erythematous, slightly raised lesions of
0.5 mm diameter called prepinpoint papules. By lateral growth,
they can lead to scaling pinpoint lesions (PP) of several millimeters
of width that precede the formation of plaques (PSO) [23].
Investigating these acute psoriatic lesions is thus expected to bring
information on the mechanisms initiating the development of the
cutaneous alterations [24,25]. Dermal changes are preponderant in
early psoriasis lesions and are characterized by papillary oedema,
dilation of both superﬁcial blood vessels and lymphatics, and by a
perivascular cellular inﬁltration in the papillary and upper
reticular layers [25]. Histochemical studies have shown that these
perivascular inﬁltrates contain monocytes and macrophages, little
lymphocytes and a large number of polymorphonuclears [25,26].
Epidermal changes comprise mild hyperplasia with slight epider-
mal parakeratosis and focal loss of the granular layer as well as
circumscribed spongiosis.
The aim of our study was to compare blood and lymphatic
vascular expansion as well as the expression of several angiogen-
esis and lymphangiogenesis markers in the uninvolved skin of
psoriasis patients (N), in early psoriasis lesions (PP) (acute pinpoint
lesions measuring 4 mm of width among patients with plaque
psoriasis) and in psoriatic plaques (PSO).
2. Materials and methods
2.1. Patients (Table 1)
Adult patients suffering of moderate to severe plaque-type
psoriasis and who had not received any systemic treatment for 1
month or any topical therapy for 2 weeks were selected (Table 1).
Their mean PASI score was 15.8. After local anaesthesia (1%
xylocaı¨ne with adrenalin), 11 patients (mean age: 43 years old, 2F/
9M, mean PASI score: 16.5) underwent skin punch biopsy (4 mm)
in a plaque lesion (PSO) and in the distant uninvolved skin (N).
Three of them (2M/1F) also presented pinpoint lesions appearing
as red, small papules of 4 mmdiameterwithmild scaling thatwere
also biopsied. In six other patients, biopsies were taken in apinpoint lesion (PP) and in the uninvolved skin at distance from the
lesion (mean age of all patients in the PP group: 40 years old, 4F/
5M, mean PASI score: 17.2). An example of a pinpoint lesion is
shown in Fig. 1.
Most of the biopsies were cut in two parts, one being ﬁxed in 3%
formalin and embedded in parafﬁn for immunohistochemistry and
the second being embedded in OCT and kept at 80 8C.
This study was approved by the Ethics Committee of the
University Hospital of Lie`ge. The patients gave their written
informed consent to participate to the study and the Declaration of
Helsinki protocols were followed.
2.2. RNA isolation and RT-PCR
Fifty mm sections from OCT-embedded biopsies were collected
and the surface of each biopsy was measured after digitization of a
section with the Axiovert 25 Zeiss microscope coupled to a CCD
camera (Carl Zeiss Vision GmbH). After washing OCT, RNA
extraction was performed by phenol/chloroform extraction
followed by glass-ﬁber ﬁlter puriﬁcation (Ribopure Kit, Ambion,
Author's Personal Copy
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K16, VEGF-A, VEGF-C, VEGFR2, VEGFR3, NRP-1, NRP-2a, prox-1,
PlGF-1 and -2 mRNA, using a Superscript II Reverse Transcriptase
(Invitrogen, Merelbeke, Belgium) and Takara Taq polymerase
(Biomedical group, Shiga, Japan). RT-PCR ampliﬁcations were
performed in an automated thermal cycler (GeneAmp PCR System
9700, Applied Biosystems, Foster City, USA) with different pairs of
primers as previously described [10,27,28]. For VEGF-A and PlGF,
forward and reverse primers were chosen in regions surrounding
the alternatively skipped sequences, allowing the discrimination of
the various splice variants on the basis of the size of their
ampliﬁcation product [29]. The ampliﬁcation products were
separated by polyacrylamide gel electrophoresis, stained (Gelstar,
Cambrex, Rockland, USA) and quantiﬁed (Fluor-S MultiImager,
Biorad, Hercules, CA, USA).
The total volume of tissue used for extracting RNA was
evaluated by multiplying the number of sections by their surface
and thickness. Quantiﬁcation of the recorded signals was
expressed in arbitrary units either per unit volume of tissue or
per unit of 28S ribosomal RNA, when appropriate.
2.3. Histology
Immunohistochemistry was performed as previously described
[10] for Ki-67 (CloneMIB-1, DakoCytomation, Glostrup, Denmark),
von Willebrand factor (Dakocytomation) and D2-40 (Proteogenix,
Illrich Cedex, France). We also performed immunohistochemistry
with anti-VEGFR3 (Clone 9D9F9, Millipore, Billerica, MA, USA)
followed by incubation with a goat anti-mouse antibody coupled
to biotin and with streptavidin coupled to peroxidase (both from
Dakocytomation). Peroxidase activity was revealed with 3-amino-
9-ethylcarbazole.
2.4. Image analysis
2.4.1. Visual image quantiﬁcation
Acanthosis score, papillomatosis score and Ki-67 labelling
index expressed as the number of Ki-67-positive cells in
percentage of the total number of basal and suprabasal cells
taken as 100% in the epidermis were evaluated as previously
described [10]. The number of cells positive for Ki-67 in the dermis
(inside and outside vascular structures, consisting, respectively in
endothelial and inﬂammatory cells) was counted in both the
superﬁcial dermis and the papillaries and normalised by stratum
corneum length. The number of lymphatic vessels positive for
VEGFR3 in the superﬁcial dermis was counted for each group of
biopsies and normalised by stratum corneum length.Fig. 2. Immunostaining of cycling cells in uninvolved psoriatic skin (N), early psoriasis sk
with anti-human Ki-67. Cycling cells were labelled with Ki-67 in N (n = 16), PP (n = 9)
calculated as the ratio of labelled cells/total basal and epibasal cells are indicated in th2.5. Semi-automatic images quantiﬁcation
Images of sections were observed and digitized as already
described [10]. An algorithm for image processing and measure-
ments was implemented, as previously described [10]. The
following parameters were measured for blood and lymphatic
vessels: (a) the average individual surface, (b) the average distance
to the basement membrane and (c) the average total surface per
area of superﬁcial dermis (dermis between the superﬁcial vascular
plexus and the dermo-epidermal basement membrane).
2.6. Statistical evaluation
Results were expressed as means  standard deviations (SD).
Statistical analysis was performed using the Mann–Whitney tests to
compare the histological parameters of the groups. Unpaired T-test
Welch corrected was applied for the RT-PCR results as normality tests
were passed (method of Kolmogorov and Smirnov). Kruskal–Wallis
tests were also performed to compare the three groups. Results were
considered to be signiﬁcant at the 5% conﬁdence level (p < 0.05).
3. Results
3.1. General tissue morphology
Acanthosis and papillomatosis scores were evaluated for the
three types of lesions (N, PP and PSO) and were signiﬁcantly
increased in PP as compared to N (Fig. 2) and further higher in PSO.
The Ki-67 labeling index was similarly increased by a factor 2 in PP
and PSO epidermis as compared to N.
As seen in Fig. 2, the PP selected in our study are nascent
psoriatic lesions that already display some degree of dermal and
epidermal changes. The papillomatosis and acanthosis scores in PP
lie between N and PSO indicating that these PP are evolving lesions
towards plaques. We therefore used them as a model to examine
the course of blood and lymphatic vascular expansion and related
transcriptional markers.
3.2. Blood vessel morphometry
Proliferating (stained for Ki-67) blood endothelial cells were
observed in the superﬁcial dermis of PP and PSO (Fig. 3). Their
number, normalised per unit of stratum corneum length, did not
signiﬁcantly differ between PSO and PP. They were most often
found in the vertical limb of dermal vessels as previously described
[30] but also in vessels beneath the basement membrane or in the
superﬁcial dermal plexus.in lesion (PP) and psoriasis plaque (PSO). Parafﬁn-embedded sections were stained
and PSO (n = 10). The mean acanthosis, papillomatosis score and Ki-67 index (%)
e table below. Scale bar = 100mm. p < 0.01 a PP vs. N; b PSO vs. PP.
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Fig. 3. Immunostaining of cycling cells (Ki-67) and lymphatic vessels (D2-40) in early psoriasis skin lesion (PP) andpsoriasis plaque (PSO). (a) and (b) Illustrate representative Ki-
67 staining of PP and PSO, respectively showing positive blood endothelial cells in dermal papillae (arrows). Serial sections in an early psoriasis lesion (c, d, g) and in a psoriasis
plaque (e, f, h)were also stainedwithD2-40 (c ande) andKi-67 (d, f, g, h) inorder to identify endothelial proliferating lymphatic cells (arrowheads in g andh). Scale bar = 100mm.
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their positivity for von Willebrand factor (Fig. 4), in PP
(385  214 mm2, mean  SD) was signiﬁcantly higher than in N
(201  65 mm2) but was however signiﬁcantly smaller than in PSO
(588  250 mm2). The number of blood vessel sections per unit
surface was 110  46 in N and almost doubled in PP (200  55,
p = 0.0001). It signiﬁcantly decreased in PSO (145  24, p = 0.004).
The average total surface of blood vessels represented 1.25  0.9% of
the superﬁcial dermis area in N. It was signiﬁcantly augmented in PSO
(4.2  1.7%), as we previously reported [10], and was found increased
to a similar extent in early PP (4.3  3.0%).
These data suggest that the percentage of dermis occupied by
blood vessels is similar in PP and PSO but that vascular network
evolves toward an enlargement of blood vessels in PSO.
We could not detect any signiﬁcant difference in the mean
distance of blood vessels to the basement membrane between the
groups (N: 84  28 mm, PP: 68  19 mm, PSO: 81  19 mm).
3.3. Lymphatic vessels morphometry
Lymphatic vessels were detected as positive for podoplanin, a
transmembrane glycoprotein recognised by anti-D2-40 antibody
(Fig. 4) and expressed by a variety of human cell types, including
lymphatic endothelium, but not by blood endothelial vessels
[31,32]. The average size of lymphatic vessels sections was similarin PP (267  117 mm2) and in N (275  225 mm2)while it was higher
in PSO (427  98 mm2). The percentage of superﬁcial dermis area
occupied by lymphatic vessels was signiﬁcantly higher in PP
(1.4  0.7%) than in N (0.36  0.30%) and further higher in PSO
(2.1  0.6%) (Fig. 4). As shown in Fig. 3, Ki-67-positive proliferating
cells were observed lining the lymphatic vessels in PP as well as in
PSO.
We previously described that lymphatics are closer to the
basement membrane in PSO as compared to N [10]. A similar
ﬁnding was observed in the series of psoriatic lesions analysed in
this study (N: 96  53 mm; PSO: 66  16 mm). The PP depicted here
had also a reduced mean lymphatic distance to basement membrane
(PP: 65  23 mm) as compared to N although at the limit of the
statistical signiﬁcance (p = 0.055).
These morphometric data indicate that blood vasculature has
already expanded in PP to an extent similar to that observed in PSO.
By contrast, the lymphatic vascular network in PP is in a
remodelling and expanding process suggesting that lymphatic
vessel development is posterior to the blood vessels expansion in
psoriasis.
3.4. Selected transcriptomic analysis
The morphometric analyses described above clearly show
epidermal alterations in PP such as increased acanthosis and
Author's Personal Copy
Fig. 4. Representative immunostaining of blood and lymphatic vessels in uninvolved psoriatic skin (N), early psoriasis skin lesion (PP) and psoriasis plaque (PSO). Serial
parafﬁn-embedded sections of N, PP and PSO skinwere stainedwith anti vonWillebrand factor (vW) and D2-40 to identify blood vessels and lymphatics, respectively in order
to perform the computer-assisted morphometry on the complete series of samples. Scale bar = 100 mm.
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compared to non-lesional skin. Inﬂammatory cells inﬁltrate has
also been described in these early lesions [26]. The contribution of
epidermal and inﬂammatory cells in the total RNA extracted from
such lesions for transcriptomic analyses is signiﬁcantly larger and
prevents a correct interpretation of the data when comparing N
and PP or PSO but also when analyzing genes originating from
dermis. To overcome this bias, the expression of a panel of selected
genes was compared in N and PP on the basis of a unit volume of
tissue. This was made possible by extracting RNA from sections of
frozen tissues in OCT of known thickness and area. Psoriatic lesions
were similarly handled. For genes known to be expressed in
epidermis and inﬂammatory inﬁltrate such as K16 and VEGF-A,
data in PP and PSO were also calculated on the basis of 28S rRNA,
enabling us to normalise the expression of those epidermal genes
on a per cell basis.Table 2
Expression of some general, angiogenesis and lymphangiogenesis markers in
uninvolved skin of psoriasis patients (N), early pinpoint lesions (PP) and psoriasis
plaques (PSO).
mRNA N (n=15) PP (n=8) PSO (n=9)
28S 6.35.6a 20.29.7b 22.919.9b
Keratin 16 14.712.2 512 319b 997846b
Angiogenesis markers
VEGF-A 121 6.03.8 22.07.9b 21.716.1b
VEGF-A 165 2.71.9 11.04.6b 8.24.8b
VEGF-A 189 0.50.4 4.62.4b 2.21.6b
VEGFR2 14.19.3 35.926.6b 39.126.8b
NRP-1 7.15.6 19.69.3b 21.115.1b
PlGF-1 12.013.4 52.740.3 48.938.6b
PlGF-2 27.719.6 10531b 125112b
Lymphangiogenesis markers
VEGF-C 15.711.0 39.88.4b 44.423.9b
VEGFR3 7.06.8 10.53.8 16.77.8b
NRP-2a 6.76.5 21.39.9b 25.118.8
Prox-1 5.86.6 1210.0 17.511.3b
Results are expressed as arbitrary units by unit of tissue volume. VEGF, vascular
endothelial growth factor; NRP, neuropilin; PlGF, placental growth factor.
a Mean standard deviation.
b Signiﬁcant statistical difference when compared to N (p<0.05).3.5. 28S rRNA and K16
The expression of 28S ribosomal RNAwas evaluated in the three
groups by unit of tissue volume (Table 2). As expected, it was
clearly increased in PP as compared to N. Its mean level was
however not further increased in PSO. Keratin 16, a marker of
proliferating epidermal cells, was also overexpressed in PP and PSO
when compared to N. When expressed per unit of 28S rRNA (Table
3), K16 was signiﬁcantly lower in PP than in PSO, consistent with
milder epidermal changes in PP and higher papillomatosis and
acanthosis scores in PSO.
3.6. Angiogenesis growth factors, receptors and co-receptors
3.6.1. VEGF-A
The expression of VEGF-A 121, 165 and 189 was signiﬁcantly
increased in PP and PSO (Table 2) as compared to N. It is
noteworthy that although the total VEGF-A was similar in PP
and PSO, the VEGF-A 189 mRNA calculated on a per cell basis
(Table 3) was signiﬁcantly overexpressed in PP as compared to
PSO (Fig. 5). The proportion of the splice variant VEGF-A 189
mRNA was indeed higher in PP (10.2  3.4%) as compared to N
and PSO (5.3  2.8% and 6.8  2%, respectively). This was further
conﬁrmed in the three patients biopsied in N, PP and PSO, who
always had a higher proportion of VEGF-A 189 mRNA in PP as
compared to PSO.Table 3
Expression of keratin 16, total VEGF-A and proportion (%) of the various isoforms of
VEGF-A in early psoriasis lesions (PP) and psoriasis plaques (PSO).
PP (n=8) PSO (n=9)
Keratin 16 3.21.1a,b 5.21.8
Total VEGF-A 2.91.4 1.90.5
VEGF-A 121% 59.63.1a 66.25.2
VEGF-A 165% 30.24.9 26.94.5
VEGF-A 189% 10.23.4b 6.82.1
Results are expressed in arbitrary units by unit of 28S rRNA and inmean percentage
of each isoform of VEGF-A in PP and PSO. VEGF, vascular endothelial growth factor.
a Mean standard deviation.
b Signiﬁcant statistical difference between PP and PSO (p<0.05).
Author's Personal Copy
Fig. 5. Electrophoretic pattern of the ampliﬁed products of VEGF-A and 28S genes.
RNA was extracted from OCT-embedded punch biopsies of early psoriasis skin
lesion (PP) and psoriasis plaque (PSO). Reverse transcription-polymerase chain
reaction (RT-PCR) was performed in duplicates for 28S and VEGF-A. The ampliﬁed
products were separated by polyacrylamide gel electrophoresis, stained with
ethidium bromide and quantiﬁed.
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As compared to N, VEGFR2, NRP-1, PlGF-1 and -2 mRNA were
increased in PP and in PSO (Table 2).
3.8. Lymphangiogenesis markers
As compared to N, VEGF-C and NRP-2a were overexpressed to a
similar level in PP and PSO (Table 2). The expression of VEGFR3 per
unit volume of tissue was increased in PSO when compared to N
(Table 2) while PP showed intermediate values. This wasFig. 6. Immunostaining of lymphatic vessels and vascular endothelial growth factor rece
plaque (PSO) were stained with anti-human D2-40 (lymphatic vessels) and anti-humaconﬁrmed at the protein level by histological staining of VEGFR3
and podoplanin in serial sections. VEGFR3-positive lymphatic
vessels were almost absent in N skin (not shown) while PP indeed
showed a number of VEGFR3-positive lymphatic vessels that
further increased in PSO (Fig. 6). We want to stress out here that
epidermal cells are negative for VEGFR3. The speciﬁc lymphan-
giogenesis marker prox-1 displayed an intermediate expression in
PP between N and PSO (Table 2).
4. Discussion
In our study, signiﬁcant morphological differences were found
between early papular lesions (pinpoint, PP) and established
psoriasis plaques (PSO). The ﬁrst evident difference was a smaller
acanthosis and papillomatosis score in PP. The percentage of Ki-67
labelled cells in the basal and epibasal layers was similar in the two
groups suggesting that epidermal cells were proliferating at a
similar rate, the epidermal compartment being however smaller in
PP. The early psoriasis lesions that we studied here already
comprise some epidermal changes in addition to the ﬁrst dermal
alterations described in the literature such as inﬂammatory
inﬁltrates and vascular changes.
Compared to N, the area occupied by blood vessels in PP was
already increased to a level similar to PSO. The vasculature pattern
however evolved during the transition between early to estab-
lished lesions by enlargement of blood vessels and a reduced
density of vascular sections. On the contrary, the area occupied by
lymphatic vessels is lower in PP than in PSO, but already increased
as compared to N. This is due to an increased lymphatic vessels
density without any modiﬁcation of their mean diameter as
compared to N. These data suggest that lymphatic vessels
development is posterior to blood vascular network expansion
in psoriasis. This is also supported by the expression of prox-1 andptor-3 (VEGFR3). Serial parafﬁn-sections of early psoriasis lesion (PP) and psoriatic
n VEGFR3. Scale bar = 100mm.
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intermediate between N and PSO while the expression of
angiogenesis markers is similar in PP and PSO. This time sequence
in human psoriasis progression can be related to lymphatic growth
that also follows blood vascular expansion during mice develop-
ment [19] and wound healing where it occurs about 1 week later
[33].
In this study, we used the 9D9F9 clone mab to detect VEGFR3.
While a positive VEGFR3 staining was observed in lymphatic
vessels in the dermis, we did not observe the intense staining in
psoriatic epidermis reported by other authors who used the
MAB3491 [34]. To further investigate a potential expression of
VEGFR3 by keratinocytes as reported by these authors, we
performed RT-PCR on resting, proliferating and differentiating
human keratinocytes in vitro with negative results (data not
shown). Similarly, RT-PCR performed on microdissection LASER
capture of normal epidermis failed to detect any VEGFR3 (data not
shown). The data reported by the team of Alitalo [35] has
demonstrated thatMAB3491 recognises a non-speciﬁc antigen and
that 9D9F9 is a more reliable antibody to investigate the
expression of VEGFR3. We therefore conclude that VEGFR3 is
not expressed in human normal or psoriatic epidermis.
Very few lymphatic vessels expressed the VEGFR3 protein in
the uninvolved skin suggesting that, similarly to the ﬁndings in
mice a few weeks after birth [36], lymphatic vasculature becomes
independent of VEGFR3 ligands in adult non-regenerating healthy
skin. VEGFR3-positive vessels are present in the dermal papillae of
PP and further increased in PSO where lymphangiogenesis is more
pronounced. The data presented here suggests that VEGFR3-
mediated signals are signiﬁcant in the development and/or
maintenance of lymphatic vessels in the psoriasis process. A role
for VEGFR3 in psoriasis is also suggested by our previous studies
showing an overexpression of VEGFR3 mRNA in uninvolved
psoriasis skin compared to skin from healthy volunteers [10]. It
is further supported by the association between psoriasis and two
single nucleotide polymorphisms in the VEGFR3 gene as well as a
higher serum level of VEGFR3 in psoriatic patients [37]. The
parallel evolution in the expression of VEGFR3 and prox-1, a
homeobox gene essential in its regulation, is a further argument
supporting the activation of lymphangiogenesis in psoriasis.
Another signiﬁcant ﬁnding in this study is the overexpression of
the VEGF-A 189 mRNA isoform in early psoriasis lesions as
compared to uninvolved skin and to psoriasis plaques. It has been
postulated that the differential localization and receptor afﬁnity of
VEGF-A isoforms might inﬂuence the behaviour of the responding
endothelium [38]. In vivo studies have suggested that heparin-
binding VEGF-A isoforms, such as VEGF 189, provide spatially
restricted stimulatory cues that polarize and thereby guide
sprouting endothelial cells during vascular branch formation,
while soluble forms lead to enlargement of lumen size [38]. The
increased expression of VEGF-A 121 mRNA in the uninvolved skin
of psoriasis patients compared to skin of healthy volunteers [10]
and the observation of a transient elevated VEGF-A 189 level in
early psoriasis lesions that we demonstrate here support the
hypothesis of a sequential and coordinated action of the various
VEGF isoforms leading to vascular expansion in inﬂammatory
processes.
It is generally admitted that vascular expansion in psoriasis is
secondary to vessel enlargement [39], elongation [40] and
increased tortuosity instead of an actual sprouting angiogenesis.
Our histological data suggest that the early psoriasis lesions, which
present a higher VEGF-A 189/VEGF-A 121 transcripts ratio,
comprise elongated and partly enlarged tortuous blood vessels.
The subsequent increase in blood vessel size observed in psoriasis
plaques compared to PP, is paralleled by a decrease in the VEGF-A
189/VEGF-A 121 transcripts balance. VEGF 189 is chemotactic forpolymorphonuclear cells, probably through VEGFR1, and can be
locally released by PMN, participating in this way in an autocrine
ampliﬁcation mechanism [41]. The numerous neutrophils already
present in the initial phases of psoriasis could be a source of VEGF
189 and then enhance the inﬂammatory process [41].
VEGF-C mRNA expression did not differ in PP and PSO and was
increased as compared to N. Other VEGFR3 ligands could be
implicated in the lymphatic vascular expansion. Some previous
reports have already implicated VEGF-A as a potent trigger of
lymphangiogenesis but it is still unclear if this effect is direct,
through VEGFR2 as described in tissue repair [33], or indirect via
up-regulation of lymphangiogenic factors.
VEGF-A as well as VEGF-C are cytokines that can constitute a
link between inﬂammation and vascular expansion in psoriasis.
Both of these molecules are secreted by inﬂammatory cells as
activated macrophages and induce the recruitment of some
immune cells expressing the corresponding VEGFR, in addition
to their (lymph)angiogenic role [42–44]. This bridge between
angiogenesis, lymphangiogenesis, which are respectively the
growth of new blood and lymphatic vessels from pre-existing
ones, and inﬂammation underline the importance of vascular
remodelling in psoriasis and the potential therapeutic perspectives
by inhibiting these processes. Furthermore, a role for lymphatic
vessels in modelling immunologic responses has recently been
described [45,46], supporting the importance to better understand
their function in psoriasis. Use of anti-(lymph)angiogenic agents in
topical application would likely avoid unwanted side effects as
observed in systemic treatments.
This work studying lesions transitional between normal skin
and psoriasis plaques emphasises a probable role for VEGF-A 189
during the development of the peculiar vascular architecture in
psoriasis. It also adds evidence for a role of VEGFR3 in the
expansion of the lymphatic network in psoriasis plaque and shows
that this expansion seems to follow that of blood vessels.
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